Crossmark

Growth factor independence underpins a paroxysmal, aggressive Wnt5aHigh/EphA2Low phenotype in glioblastoma stem cells, conducive to experimental combinatorial therapy

Crossref DOI link: https://doi.org/10.1186/s13046-022-02333-1

Published Online: 2022-04-12

Published Print: 2022-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Trivieri, Nadia

Visioli, Alberto

Mencarelli, Gandino

Cariglia, Maria Grazia

Marongiu, Laura

Pracella, Riccardo

Giani, Fabrizio

Soriano, Amata Amy

Barile, Chiara

Cajola, Laura

Copetti, Massimiliano

Palumbo, Orazio

Legnani, Federico

DiMeco, Francesco

Gorgoglione, Leonardo

Vescovi, Angelo L.

Binda, Elena https://orcid.org/0000-0002-8750-2905
Funding

Funding for this research was provided by:

Ministero della Salute (GR-2011-02351534, Progetto Ricerca Corrente 2018-20)

Associazione Italiana per la Ricerca sul Cancro (IG-22027)
License Information

Text and Data Mining valid from 2022-04-12

Version of Record valid from 2022-04-12
More Information

Article History

Received: 22 November 2021

Accepted: 17 March 2022

First Online: 12 April 2022

Declarations

:

: Patients with a confirmed diagnosis of glioblastoma multiforme were enrolled in this study at IRCCS National Neurologic Institute “C. Besta” under the Ethical committee approvals number Prot.61. All the subjects agreed to participate according to the ethical guidelines of the 2013 Declaration of Helsinki and signed an informed consent for samples and anonymized information to be used. All the experimental procedures for the in vivo mice studies have been approved by the Ministry of Health (prog. N°7/2010 and 7/2013).

: All authors have seen and approved the manuscript and consent publication.

: The authors declare no competing interests. AL Vescovi has ownership interest in Hyperstem SA.

Document is current

Any future updates will be listed below